CT Evaluation of Intimal Flap Mobility (CT-MOBILITY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03787277|
Recruitment Status : Recruiting
First Posted : December 25, 2018
Last Update Posted : February 15, 2019
Type A aortic dissection is an emergency condition, defined by the appearance of an intimal flap within the ascending aorta. Urgent treatment is required, with surgical replacement of - at minima - the tubular portion of the ascending aorta.
After surgery, a majority of patients will still have a residual aortic dissection involving the aortic arch and/or the descending aorta. Long-term survival in these patients can be hindered by the apparition of an aneurysmal progression of the dissected aorta, with risk of rupture, thrombose and/or embolism. Consequently, this condition requires frequent follow-up imaging examinations, usually by Computed Tomography Angiography (CTA), to monitor the extension of the dissection and the diameters of the dissected aorta. Patient management is therefore based on passive follow-up of the disease, as no definitive clinical or imaging features can predict the potential evolution (or the absence of) towards an aneurysmal evolution.
Therefore, one can understand the important need for accurate predictors of aneurysmal dilatation of post-operative residual dissection.
CTA has the ability to visualize the intimal flap motion, by averaging at least 3 or 4 cardiac cycles over a non-gated arterial acquisition.
This intimal flap mobility varies greatly between patients, between the localization and the extension of the dissection, and between acute and chronic dissections. It is thought that chronic dissections with immobile flap might be less prone to aneurysmal evolution.
The investigators hypothesize that this mobility could be a prognostic marker for the evolution towards aortic dilatation: flap that would remain highly mobile after initial surgery could be an additional marker towards an aneurysmal evolution, while immobile flap could be on the contrary a marker of stability.
Intimal flap motion can already be qualitatively and quantitatively assessed in CTA when ECG-synchronization is used. However, this technique has a limited availability and significantly increases the total radiation dose, therefore limiting its use in routine practice. Being able to quantify this marker using routine non ECG-gated CTA could be a significant addition to the literature, as it is currently unknown if this is feasible/relevant.
|Condition or disease|
|Aortic Dissection Type A|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||CT Evaluation of Intimal Flap Mobility as a Potential Predictor of Residual Type B Dissection Evolution|
|Actual Study Start Date :||January 8, 2019|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
- Evaluate the mobility of the intimal flap with CT angiography without the use of ECG synchronization [ Time Frame: The period from January 1st, 2010 to December 31, 2015 will be examined ]The study concerns patients operated at Strasbourg University Hospitals for the replacement of the ascending aorta for aortic dissection from 2010 to 2015
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787277
|Contact: Mickaël OHANA, MD||33 3 69 55 11 email@example.com|
|Contact: Joseph ATLAN, MD||33 3 69 55 10 firstname.lastname@example.org|
|Service de Radiologie B - NHC||Recruiting|
|Contact: Mickaël OHANA, MD 33 3 69 55 11 17 email@example.com|
|Contact: Joseph ATLAN, MD 33 3 69 5510 83 firstname.lastname@example.org|
|Principal Investigator: Mickaël OHANA, MD|
|Sub-Investigator: Joseph ATLAN, MD|